CRVS - Corvus Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Currency in USD

Valuation measures4

Market cap (intra-day) 95.47M
Enterprise value 55.76M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)1.70
Enterprise value/revenue N/A
Enterprise value/EBITDA -1.78

Trading information

Stock price history

Beta (5Y monthly) 1.17
52-week change 3152.43%
S&P500 52-week change 32.54%
52-week high 33.7000
52-week low 30.6070
50-day moving average 31.4363
200-day moving average 31.0091

Share statistics

Avg vol (3-month) 3773.67k
Avg vol (10-day) 32.18M
Shares outstanding 546.57M
Implied shares outstanding 6N/A
Float 832.07M
% held by insiders 13.98%
% held by institutions 145.91%
Shares short (14 May 2023) 4455.53k
Short ratio (14 May 2023) 40.49
Short % of float (14 May 2023) 41.32%
Short % of shares outstanding (14 May 2023) 40.98%
Shares short (prior month 13 Apr 2023) 4238.74k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2022
Most-recent quarter (mrq)30 Mar 2023


Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-24.48%
Return on equity (ttm)-59.00%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -30.89M
Net income avi to common (ttm)-40.88M
Diluted EPS (ttm)-0.7800
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)34.47M
Total cash per share (mrq)0.74
Total debt (mrq)2.3M
Total debt/equity (mrq)4.71
Current ratio (mrq)4.29
Book value per share (mrq)1.05

Cash flow statement

Operating cash flow (ttm)-28.71M
Levered free cash flow (ttm)-17.85M